This phase II study is assessing how safe and effective new targeted therapy (MORAb-202) is in people with previously treated, metastatic non-small cell lung cancer adenocarcinoma.
This trial is treating patients with non-small cell lung cancer adenocarcinoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 2, Open-label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies
Bristol-Myers Squibb (BMS)
Eligible participants will be randomly allocated to receive MORAb-202 at either Dose Level 1 or Dose Level 2.
Recruiting Hospitals Read More